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The present study has investigated the in vitro ibuprofen release profiles from a liquid 
crystalline system, which is composed of cholesteryl nonanoate (CNN), cholesteryl 
chloride (CCL) and cholesteryl oleyl carbonate (COC), with a combination ratio of 
CNN/COC/CCL=10/80/10 w/w/w.  The presence of organized liquid crystalline 
structures was confirmed by polarizing light microscopy and x-ray diffraction, and the 
structures were shown to remain relatively unchanged after drug loading.  The inclusion 
drug molecules remained in a molecularly distributed amorphous state as no crystalline 
drug evidence was found in the matrix as shown by DSC and x-ray diffraction studies.  
Drug-carrier interactions were probably mediated through van de Waals or dipole-dipole 
interactions because FTIR spectra revealed absence of hydrogen bonding interaction 
within the liquid crystalline matrix.  The in vitro ibuprofen release profiles most aptly 
fitted to the square root Higuchi release model, indicating that drug release was 
predominantly controlled by Fickian diffusion.  Drug release was influenced by the phase 
transition of the liquid crystalline matrix, initial drug loading, as well as the viscosity of 
the matrix system.  
 vii
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CHAPTER 1. INTRODUCTION 
 
1.1  Problem Statement  
Ibuprofen (IBU), α-methyl-4-(2-methylpropyl)-benzene acetic acid, is a non-steroidal 
anti-inflammatory drug (NSAID) used to treat rheumatoid arthritis, osteoarthritis and 
mild to moderate pain.  The gastrointestinal irritation and ulcerogenic effects along with 
short half-life (1.8 - 2.0 h) of IBU have led to the design of sustained release formulations 
of IBU (Maheshwari et al. 2003).  Due to its low melting point and hydrophobic nature 
(log P = 3.5), it was chosen as a model drug in this study. 
 
Liquid crystals as drug delivery systems have been reported to be able to improve the 
dissolution of poorly water-soluble drugs.  It is known that lyotropic liquid crystalline 
phases can provide a slow release matrix for incorporated active molecules (Drummond 
and Fong, 1999).  Lyotropic liquid crystalline phases have the ability to incorporate 
solutes (drugs) into their structures and the release behavior of the incorporated drugs 
obeyed Higuchian kinetics in many cases (Boyd et al. 2006, Shah et al. 2001).  
Thermotropic liquid crystalline phases have similar potential to incorporate hydrophobic 
drugs and the change of the physical structure can be controlled by temperature change in 
many reports (Lin et al. 2000, Dinarvand et al. 2006).  However, until recently, there 
have been few reports on the drug release mechanism from thermotropic liquid 
crystalline systems.   
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Drug release rate from the liquid crystalline matrix is dependent on several factors related 
to both the drug and the matrix.  These factors include temperature, initial drug loading, 
water content, the structure of the system as well as the physical properties of the 
incorporated drug.  These factors are critical in understanding the drug release 
mechanism from the liquid crystalline matrix and thus,require more in-depth studies.  
 
1.2 Purpose of the Study and Objectives 
The purpose of the project is to develop a drug delivery system that releases drugs in a 
controlled manner in response to changes in temperature.  
The specific objectives of the project are: (a) investigate in vitro drug release mechanism 
from the liquid crystalline structure; and (b) correlate drug release kinetics with 
temperature change, initial drug loading and system viscosity.  
 
1.3 Research Hypothesis and Rationale for Hypothesis  
It is hypothesized that liquid crystals of similar chemical structures can be mixed together 
to form a single composite liquid crystal.  By mixing the components in different ratios, it 
is possible to design a liquid crystalline system with a desirable phase transition 
temperature.  Because of their hydrophobic nature and liquid crystalline structure, liquid 
crystal mixtures are able to incorporate hydrophobic drugs.  Phase transition temperature 
would influence the structure of the liquid crystalline system, thus acting as an on / off 
switch for the release of the incorporated drug.  The drug release from the liquid 
crystalline system will follow a certain drug release mechanism, and be influenced by 
several factors.  
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CHAPTER 2. THE MESOMORPHIC STATE: LIQUID CRYSTALS 
 
2.1 Liquid Crystal Definition, Classification and Network Structure 
 
In 1888, Reinitzer observed that on heating, cholesteryl benzoate “melted” first to a 
viscous turbid liquid and then, some degrees higher, became optically clear.  In 1889, 
Lehmann studied the intermediate turbid phase and called it “Fliessende Krystalle” or 
“Flűssige Krystalle” (flowing or fluid crystals).  Friedel called this the mesomorphic state, 
i.e. a state between solid and liquid (Brown et al. 1957).  
 
Liquid crystals are typically elongated organic molecules with an uneven distribution of 
electrical charges along their axes (dipole).  This gives rise to a special physical 
characteristic to which liquid crystals owe their name: between the crystalline and liquid 
statesthey exhibit a further state of aggregation, namely the liquid crystalline or 
mesophase.  In this phase, the liquid crystal molecules are aligned parallel to each other 
but are able to rotate about their long axes.  
 
A prerequisite for the formation of liquid crystalline phases is an anisometric molecular 
shape, which is generally associated with a marked anisotropy of the polarizability.   
Molecules that can form mesophases are called mesogens.  The latter are often excipients  
e.g. surfactants.  Even drug compounds themselves, e.g. the salts of organic acids or 
bases with anisometric molecular shape, may fulfill the requirements for the liquid crystal 




Liquid crystal formation by drugs (Müller-Goymann, 2004) 
 
Drug Type of liquid crystal 
Arsphenamine Nematic 
Disodium cromoglicinate Nematic, hexagonal 
Nafoxidin-HCl Hexagonal, cubic, lamellar 
Diethylammonium flufenamate Lamellar 







Peptide hormone LH-RH analogue  
 
Starting with the crystalline state, the mesophase is reached either by increasing the 
temperature or by adding a solvent.  Accordingly, thermotropic or lyotropic liquid 
crystals are formed.  As with thermotropic liquid crystals, variation in temperature can 
also cause a phase transformation between different mesophases of lyotropic liquid 
crystals.  
 
There are different types of molecular arrangement in thermotropic liquid crystals: 
smectic, nematic or cholesteric.  The term smectic (soap-like) was coined by Friedel 
(Oswald et al. 2005) from the Greek σμεγμα, meaning grease or slime.  The smectic 
structure is stratified as the molecules are arranged in layers with their long axes 
approximately normal to the plane of the layers.  The term nematic was coined by Friedel 
from the Greek νημα, meaning thread.  The term is used literally to describe the thread-
like lines which are seen in the nematic structures under microscopic observation.  In the 
nematic structure, the only restriction on the arrangement of the molecules is that the 
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molecules preserve a parallel or nearly parallel orientation.  A third structure has been 
described in the literature, the cholesteric, so called because it is shown mainly by 
cholesteryl derivatives.  
 
(c) nematic(a) crystal (b) smectic (d) liquid  
Fig 2.1 Thermotropic liquid crystals (with the increase of temperature): (a) crystal ; (b) 
smectic; (c) nematic; (d) liquid.  
 
 
Materials that form liquid crystals by addition of solvents are referred to as lyotropic 
liquid crystals, i.e. when present in aqueous solutions the concentration of water-soluble 
amphiphiles is increased.  The amphiphilic molecules must exhibit some chemical 
complexity otherwise they will dissolve in the solvent instead.  Liquid crystals are 
typically organic molecules, ranging from small molecules (e.g. detergents) to 
polyelectrolytes (e.g. DNA, vegetable gums).  The formation of lyotropic mesophases is 
driven by the chemical structure of the organic molecule(s), the ratio of water to 
amphiphile(s) and the temperature.  With decreasing water concentration, hexagonal 
(similar to many cylinder-like micelles) and then lamellar phases (similar to stacked 
bilayers, discoid) are formed.  In the case of molecules with very polar head groups 
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which has high water binding capacities, cubic phases (“balls”) may be formed instead of 
hexagonal arrangement.  
 
The mesophase classifications and characteristics are summarized in Table 2.2. 
 










a) Thermotropic  











Temperature Rigid part + 
one/two flexible 
aliphatic chains 





b) Lyotropic  











2.2 Lyotropic Liquid Crystals  Surfactants (surface-active agents) are materials that 
possess both a polar entity (the head group) and a non-polar paraffin chain in the same 
molecule.  
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When water is added to solid surfactants, three types of behavior can occur: 
(1) The surfactant is practically insoluble, and remains as a solid crystal plus an 
aqueous solution of surfactant monomers.  
(2) Some of the surfactant dissolves to form an aqueous micellar solution.  
(3) A lyotropic liquid crystal is formed above certain concentration.  
 
Surfactants that are almost insoluble in water are non-polar and semi-polar lipids, and 
polar surfactants at temperatures below the Krafft point.  Above the Krafft point, most 
surfactants have a narrow temperature region (≈10K) where they form micelles but not 
liquid crystals.  Over most of the temperature range between the Krafft point and the 
surfactant melting point, lyotropic liquid crystals are formed.  Within the temperature 
range 273-473K, lyotropic liquid crystals occur at least as frequently as micellar solutions, 
if not more so.  Some surfactants that do not form micelles can form liquid crystals.  
 
Lyotropic liquid crystals are frequently encountered in everyday life, although their 
presence is not normally recognized.  They occur during the dissolution of soaps and 
detergents, and a few products of this type are even sold in a liquid crystalline form.  
They occur also during cooking, for example, cake batters often contain a liquid crystal 
stabilized emulsion.  In the industrial sector, the best known example of the use of 
lyotropics is the occurrence of neat phase during soap manufacture.  Similar phases occur 
during the processing of other detergent products.  For biologists, the bilayer arrangement 
of molecules in the lamellar liquid crystalline phase is commonly encountered since this 
unit forms the fundamental structure of most biological membranes.  
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The most common lyotropic liquid crystalline structure is the lamellar phase, followed by 
the hexagonal phase and the reversed hexagonal phase (Fig.2.2).  Least common are the 
various cubic phases which are normally observed only over limited temperature and 
composition ranges.  In considering the factors responsible for the formation of any 
lyotropic liquid crystalline phase, two properties of the particular surfactant(s) appear to 
be important.  These are: 
(1) The magnitude of the repulsive forces between adjacent head groups at the 
surfactant / water interface.  Important factors here are the head group, 
strength of head group hydration and alkyl chain steric requirements and 
whether the adjacent surfactant molecules have like, unlike or zero charge.  
(2) The degree of alkyl chain/water contact and the amount of conformational 
disorder in the alkyl chains which are influenced by the number, length and 
degree of unsaturation of the alkyl chains.  
 
(a)              (b)           (c)           
Fig 2.2 Lyotropic liquid crystals: (a) hexagonal mesophases; (b) cubic mesophases; (c) 




2.3 Thermotropic Liquid Crystals 
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Common thermotropic liquid crystals are composed of derivatives of cholesterol, 
C27H46O.  The cholesteric derivatives (cholest-5, 6-en-3β-R) are made up of 27 carbon 
atoms and have 17 of these carbon atoms bonded together in such a way as to form a 
rugged, not easily deformed nucleus or skeleton.  These 17 carbon atoms are held 
together in three six-numbered rings and one five-numbered ring; a pattern which is 
quasiplanar.  At one edge of the skeleton are three side chains, two of which are made up 
of only one carbon atom.  The 17β substituent consists of a chain of eight carbon atoms.  
All of these chains project above the plane of the skeleton.  At the opposite end of the 
skeleton and also projecting out of a plane, an R group is attached in the 3β position.  The 
3β substituent extends the molecular long axis and favors mesophase formation.  The 
mesophase is formed by cholesteric derivatives only when the substituents are in the 3β 
position, and when rings A and B are quasiplanar.  The 17β side chain is not a critical 
















Fig 2.3 Chemical structure of cholesteryl esters (R= CxHy, number of carbons: 1 to 20+, 




Characteristically, cholesteryl esters exhibit two mesophases: the smectic mesophase and 
the cholesteric mesophase.  The smectic mesophase is a slightly turbid, viscous state 
which displays focal conic textures with a positive sign of birefringence under a 
polarizing microscope.  The cholesteric mesophase appears at temperatures higher than 
the smectic mesophase and is also slightly turbid, but is more fluid than the smectic phase 
and often exhibits a variety of colors by virtue of its long-range twisted or helical 
structure.  Microscopically, this mesophase exhibits focal-conic textures with a negative 
sign of birefringence.  
 
The estimated thickness of the sterol region of the saturated esters is 17 Ǻ which isclose 
to the extended length of the cholesterol molecule (17.5 Ǻ), indicating that the sterol axis 
lies nearly normal to the smectic planes.  The thickness of the cholesterol region of the 
monounsaturated series is only 13.8 Ǻ, and this suggests that the sterol axis is tilted about 
54˚ with respect to the smectic phase.  Thus, the saturated series appears to be a smectic 
A liquid crystal (molecular along axis normal to smectic planes), while the unsaturated 
series is a smectic C liquid crystal (molecular long axis tilted with respect to the smectic 
planes). 
 
Ring ordering is apparently an important feature of liquid crystalline phases of 
cholesteryl esters, and a higher degree of ring ordering is characteristic of the formation 
of a cholesteric phase.  In fact, calorimetry studies on dicholesteryl esters have shown 
that these lipids undergo a cholesteric→isotropic liquid phase transition, with at least 
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twice the expected entropy, indicating that the steroid ring interactions are important in 
ordering the cholesteric phase.  
 
Droplets of cholesteryl esters appear histologically or submicroscopically in a variety of 
normal and pathological cellular processes.  For example, cholesteryl ester droplets have 
been described in neural tissue prior to nerve myelination.  The presence of a cholesteryl 
ester-rich core characterizes the lipoprotein particles responsible for cholesterol transport 
in the blood to and from the tissues. 
 
2.4 Phase Transition between States 
 
The temperature at which the crystal lattice collapses is known as either the melting point 
or the transition point, while the temperature at which the true liquid is obtained has been 
referred to as the clarification point, clearing point, transition point, or melting point.  
 
The transitions from the completely ordered solid crystal through the smectic and nematic 
structures to the true liquid may be outlined as follows (Brown et al. 1957): 
1. Three-dimensional crystal.  Apart from vibration, the centers of gravity of all 
lattice units are fixed; rotations are not possible.  
2. Crystal with rotating molecules.  The centers of gravity of all lattice units are 
fixed; rotation about one or more axes is possible. Example: butyl halides. 
3. Smectic structure.  The centers of gravity of the units (molecules) are mobile in 
two directions; rotation about one axis is permitted.  
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4. Nematic structure.  The centers of gravity of the units (molecules) are mobile in 
three directions; rotation about one axis is permitted. 
5. True liquid.  The centers of gravity of the units are mobile in three directions; 
rotation about three axes perpendicular to one another is possible.  
 
If chain-chain interactions are weak, a cholesteric phase will be formed.  On the other 
hand, if chain-chain interactions are strong, as in the case of esters with a long distance 
between the ester group and the first double bond, then a stable smectic phase will be 
formed before ring-ring interaction is strong enough to nucleate a cholesteric phase.  
Finally, if the chain is saturated and long, nucleation and crystallization will occur at 
temperatures above the temperature of potential formation of the liquid crystals and no 
liquid crystalline phases can be formed.  
 
The liquid crystalline phases of cholesteryl esters can occur as either stable or metastable 
phases.  A stable mesophase forms as the crystal melts and is called an “enantiotropic” 
transition, whereas a metastable mesophase forms at a temperature below the crystal melt 
and thus forms from an under-cooled isotropic liquid (also known as a “monotropic” 
phase transition).  Stable mesophases can exist indefinitely in the temperature range 
above the crystal melt and below the isotropic liquid phase transition.  Metastable 
mesophases will either crystallize rapidly or can remain for long periods but eventually 
will nucleate or can be nucleated with crystalline ester to form true crystals - the more 
thermodynamically stable state (Ginsburg et al. 1984). 
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Nearly all the liquid crystal transitions are almost perfectly reversible (assuming the 
nucleation and crystallization do not occur prior to reheating).  If, however, 
crystallization occurs to a crystal of higher melting point, no liquid crystalline 
transformations will occur on reheating, and the crystal will simply melt to an isotropic 
liquid.  Specifically, cholesteryl esters having a chain length greater than C16 have the 
metastability and no mesophases are observed in saturated esters with greater than 20 
fatty acyl carbons.  These long chain esters have high crystal→isotropic transition 
temperatures and lack significant undercooling on crystallization.  
  
The liquid state is characterized by a high degree of fluidity and relatively low viscosity..  
Liquids, under polarized light, display no birefringence and thus are called isotropic or 
zero-dimensional order states.  However, X-ray scattering of cholesterol and cholesteryl 
esters in the liquid state shows two broad maxima (similar to scattering from the 
cholesteric phase, but broader and lower in intensity).  Using molybdenum Kα radiation, 
it was found that the diffraction-intensity curves are practically the same but that the 
intensity at the principal maximum is 5 to 15 percent greater for the nematic structure 
than for the liquid structure.  Sharper peaks with steeper inner slopes with the nematic 
structure indicate more regularity of structure in that phase.  
 
2.5 Mixed Liquid Crystals 
 
In the case of a mixture of two different substances both with asymmetric molecules, two 
factors will influence the ease of formation of liquid crystals: (1) the ability of the 
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molecules to pack into a single liquid-crystalline “lattice” and (2) the decrease in energy 
on the orientation of the liquid.  If the two components are similar in size and shape, the 
steric factors will be uniform for mixtures of all compositions.  If the molecules of the 
two components differ in size and shape there will be more difficulty in packing them 
together.  The transition temperature should be less than that predicted for the “ideal” 
behavior considered previously.   
 
Mesophases could act as ideal liquid mixtures wherein exists a uniformity of cohesive 
forces.  In such a situation, the intermolecular forces between like and unlike molecules 
are essentially equivalent.  Application of Raoult’s law suggests that the melting 
temperature should be a linear function of the composition (at constant pressure) .  It may 
be recalled that all mesophase-isotropic and mesophase-mesophase transitions are 
relatively small; so small that the degree of order lost at these transitions cannot involve 
the liberation of rotations of the ester tail.  For rotation of a single C-C bond, the entropy 
for three rotational positions is over ten times the rate of mesophase transition entropy 
increase per CH2 in the ester tail.  This implies that the mesophase structures are 
predominantly influenced by the steroid moiety and in only a minor but real way by the 
ester tail.  Thus one ester does not - and indeed should not - note a second ester as an 
impurity that must be excluded from the mesophase structures (Galanti et al. 1972).    
 
2.6 Viscosity 
If a liquid crystalline network or matrix is formed by amphiphilic molecules, the 
microstructure of ointments or creams may be liquid crystalline.  In this situation, the 
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system is more easily deformed by shear stress.  Such formulations show plastic and 
thixotropic (decreasing viscosity under constant shear rate) flow behavior.  Systems with 
a liquid crystalline matrix exhibit a short regeneration time after shearing.  In comparison, 
a crystalline matrix is usually destroyed irreversibly by shear.  
 
Several investigators (Brown et al. 1957) have compared data on the viscosity of 
substances that exhibit the mesomorphic state with the viscosity of emulsions.  In general, 
these authors concluded that that the mesomorphic state and emulsions show viscosity 
characteristics that are very similar.  Paasch et al. (1989) carried out a more systematic 
rheological study of several nonionic surfactant-water lamellar liquid crystalline phases 
and found that these phases exhibited shear thinning behavior and yield stresses.  Németh 
et al. (1998) reported a dynamic rheological method for the identification of 
pharmaceutically important lamellar phases.  Among the main types of lamellar liquid 
crystalline systems, mesophases with a lamellar structure that demonstrate the greatest 
similarity to the intercellular lipid membrane of the skin are primarily recommended for 
the development of a dermal dosage form (Roux et al., 1994; Vyas et al., 1997). 
 
In the presence of a minimum quantity of water, the enthalpy change in going from a 
liquid crystal to a micellar solution is always much smaller than that involved in crystal 
→ liquid crystal or crystal → liquid transitions.  The latter two are similar in magnitude. 
This holds for nonionic and ionic systems.  Also, measurements of water activities show 
little difference between micellar solutions or liquid crystals of different structures, again 
indicating that the main interactions are similar in both.  It has been suggested that the 
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transitions may be mainly entropic but enthalpy changes are likely to be important as well 
(Tiddy, 1980).  
 
In a lamellar phase, the lipid layers can move over each other easily.  However, 
movement along the uni-axis would be expected to be much more difficult, because of 
the distortion or re-alignment of bilayers that this would require.  For a hexagonal phase, 
the rods would be expected to move in the direction of the long axis as easily as lipid 
lamellae can slide over each other.  Movement perpendicular to this direction involves 
modification of the hexagonal packing, disruption of the rods, etc., and again is more 
difficult.  Cubic phases have no easy flow direction because the aggregates repel each 
other in a three dimensional network.  Thus the viscosity of the various phases would be 
expected to increase in the order lamellar < hexagonal < cubic.  While generally this is 
observed in practice, other more complex behavior that can obscure this pattern also 
occurs.  Within a particular phase, any change which reduces interactions between 
aggregates such as addition of uncharged amphiphiles to ionic surfactant systems leads to 
a decrease in viscosity.  The reduction can be large when salt is added to decrease 
electrostatic repulsion in liquid crystals containing ionic surfactants.  
 
A relatively complete study of the viscosity of cholesteryl myristate at different shear 
rates using a column and plate viscometer was conducted by Sakamoto (Ginsberg et al., 
1984).  Both the smectic and the cholesteric phases are clearly non-Newtonian and their 
viscosities decrease with increasing shear rate.  The isotropic phase measured at one 
degree above the cholesteric- isotropic transition appears to be Newtonian.  The nearly 
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linear decrease in the log of viscosity vs. shear rate indicates that the viscosity of both the 
smectic and the cholesteric phases will reach a limiting value of viscosity similar to the 
isotropic phase at higher shear rates.  The cholesteric phase is much more sensitive to 
shear rate than the smectic phase.  The authors believe that the structures of the smectic 
and cholesteric phases were disrupted at these high shear rates.  The energies of flow 
activation may be calculated from a plot of the log of viscosity vs. 1/ T.  For cholesteryl 
myristate, the activation energies in kcal/mol are 11 to 16 for liquid crystalline states and 
about 8 for the isotropic liquid state.  
 
2.7 Liquid Crystal Stabilization 
 
The first step in stabilizing liquid crystalline formulations is to isolate the liquid crystal 
from the atmosphere by a protective barrier and preferably, at the same time, to convert it 
into an easily manipulable form.  If the primary protection against degradation is 
provided by some sort of physical packaging, then secondary protection can be achieved 
by incorporating stabilizing (UV absorbing) properties into the materials used in 
conjunction with the liquid crystals to make devices.  The clear polymer substrates to 
which the packaged liquid crystal is applied and the polymer systems (ink or paints) 
which either contain the packaged liquid crystal or are applied to it to protect it, are the 
best examples of hosts for stabilizers.   
 
To date, the microencapsulation process has been the most versatile, widely applicable 
and successful way of stabilizing, packaging, and protecting liquid crystal mixtures.  The 
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liquid crystal is isolated from the atmosphere outside by a protective barrier and at the 
same time, converted into a comparatively easy-to-use form.  In simple terms, a 
microcapsule is a small sphere with a uniform wall around it and in the 
microencapsulation process, tiny droplets of liquid crystal are surrounded with a 
continuous polymer coating to produce discrete microcapsules.  Microcapsule diameters 
















CHAPTER 3. APPLICATION OF LIQUID CRYSTALS AND LIQUID 
CRYSTALLINE FORMULATIONS 
 
3.1 Application of Liquid Crystals in Daily Life 
 
Technically speaking, liquid crystals of the nematic type are by far the most important.  
They are used in electro-optic display systems: liquid crystal displays (LCD).  In order to 
achieve a combination of properties suited for a particular application, liquid crystal 
mixtures consisting of 10, 20 – in individual cases of as many as 30 or more – single 
liquid crystal substances are needed. 
 
If smectic and nematic liquid crystals are subjected to temperature changes, they change 
their form and their light transmission properties, splitting a beam of ordinary light into 
two polarized components to produce the phenomenon of double refraction.  This results 
in the appearance of the characteristic iridescent colors of these types of liquid crystals.  
This type of liquid crystal finds use in thermometers, egg timers, and other heat sensing 
devices.  Changes in structure can also be accomplished using a magnetic field, which 
make them useful in calculators or other LCD displays.   
 
Several studies have found the use of cholesteric liquid crystals in clinical thermometry. 
Liquid crystals embedded in a self-adhesive polymer film have been marketed in the 
form of a tape to obtain the thermal mapping of skin in medical application.  This 
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technique is used for temperature sensors to detect illness in human beings by reflecting 
the skin temperature patterns from the liquid crystal thermography.  
 
When lyotropic liquid crystals are subjected to disturbances such as stirring or squeezing, 
the disturbed layers of crystals alter their light transmission characteristics to produce 
color changes similar to the smectic and nematic liquid crystals described above. These 
are the type of liquid crystals used in the Press Me stickers 
(http://mrsec.wisc.edu/Edetc/nanolab/LC_prep/index.html). 
 
3.2 Application of Liquid Crystal Formulations in Drug Delivery 
Liquid crystals as delivery systems can potentially improve the dissolution of poorly 
water-soluble drugs.  Lyotropic liquid crystals can incorporate relatively high drug 
loadings, but the disadvantages are that the tenside concentrations are high and that 
colloidal dispersions of liquid crystals occur only in a narrow range of parameters.  




Examples of applications of liquid crystal formulations in drug delivery 
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3.2.1 Lamellar phases 
 
Lamellar lyotropic liquid crystalline systems are thermodynamically stable, optically 
isotropic systems formed with low energy input.  The lamellar phase has a long-range 
order in one dimension.  Its structure consists of a linear arrangement of alternating lipid 
bilayers and water channels.  New possibilities for the development of controlled drug 
delivery systems are inherent in these systems due to their stability and special skin-
similarly structure.  
 
Only a small amount of work reported in the literature specifically examine the use of 
lamellar phases.  Yet lamellar phase structures exhibit interesting solubility properties in 
that the lamellar lipophilic bilayers structure alternate with hydrophilic layers that contain 
inter-lamellar water making them suitable for incorporating water-soluble, oil-soluble, 
and amphiphilic drugs.  Furthermore, evidence suggests that some drugs are more soluble 
in the liquid crystalline lamellar phase than in isotropic liquids of similar composition 
(Wahlgren et al., 1984).  
 
The diffusion coefficient of a drug within a liquid crystalline phase is about one to two 
orders of magnitude smaller than in solution (Müller-Goymann et al., 1986) because 
liquid crystals have a highly ordered microstructure and an increased viscosity.  In order 
to control drug release, the drug solution needs to transform into a liquid crystalline 
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system on contact with biofluids after application.  In the work of Müller-Goymann et al. 
(1993), fenoprofen acid (FH) and fenoprofen sodium salt (FNa) were chosen because 
even the drug itself is able to form liquid crystals in presence of water.  FNa appeared to 
increase liquid crystal formation, which improved the growth of liquid crystalline layer 
and slowed down drug diffusion; while FH destabilized liquid crystal and increased the 
drug diffusion rate.  The reason was due to the Van der Waals-London interactions for 
both FH and FNa, and also polar interactions that were stronger than hydrophilic ones in 
case of FNa.  
  
Generally, a drug permeating through a lamellar gel network may follow an inter-
lamellar or trans-lamellar route, depending on local rates of diffusion and partition.  
Extremely lipophilic drugs are likely to be trapped inside the lipophilic bilayers while 
extremely hydrophilic drugs will permeate through the hydrophilic regions between the 
lamellae and amphiphilic drugs may move both between and across the lamellae.  For 
extremely hydrophilic drugs, the inter-lamellar aqueous channels behave as pores, the 
tortuosity of which is determined by the amount of free water and the orientation of the 
lamellae (Geraghty et al. 1996).  Makai et al. (2003) reported a lamellar system 
containing Brij 96 (poly-oxyethylene-10-oleyl ether) with water, liquid petrolatum and 
glycerol which was incorporated with hydrophilic drug ephedrine hydrochloride or 
hydrophobic drug tenoxicam.  An increase in the inter-lamellar distance was detected in 
case of both incorporated model drugs which meant that the drugs were partly built 
between the lamellar space and partly located at the given polarity part of the amphiphilic 
surfactant molecules.  
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Lamellar phase is inherently fluid and can be injected using a syringe but drug release is 
short-term and likely to cause a burst in release which may result in dose dumping (Shah 
et al., 2001).  One potential problem with topical application of lamellar phases is that 
dehydration of the skin may occur, resulting in irritation.  
 
3.2.2 Cubic phases 
The structure of the cubic phase consists of curved lipid bilayers extending in three 
dimensions separated by two congruent networks of water channels.  It is formed 
spontaneously in contact with water and stays in equilibrium with excess water (Shah et 
al. 2001).  The cubic phase has a transparent, stiff, gel-like appearance and has recently 
proved to possess bioadhesive properties (e.g., it sticks effectively to the skin).  Another 
important feature with regards to drug delivery is that it is biodegradable (Wallin et al., 
1994).  The cubic phase has been reported to act as a drug delivery system for a number 
of drugs (Table 3.1) Due to the amphiphilic nature of the cubic phase, both hydrophilic 
and lipophilic drugs can be incorporated.  
 
The interfacial area of cubic phase is about 400 m2 /g and the pore size of fully swollen 
cubic phases is about 5 nm (Engstrom et al., 1995; Wyatt and Dorschel, 1992).  A typical 
globular protein has same size as the dimensions of water channels in the bicontinuous 
cubic phases.  Protein entrapment in the cubic phase depends on the type of protein, its 
interaction with the lipid bilayer and dimensions of the water channels.  It is difficult to 
incorporate macromolecular enzymes in the cubic phase, since this can modify the 
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structure of protein and cubic phase.  However, the enzyme-like glucose oxidase (M.W. 
160 kDa) has been successfully entrapped in cubic phase.  
 
Various researchers have been working on the cubic phase as carrier for drug delivery 
system.  Wyatt and Dorschel (1992) demonstrated that the cubic-phase matrix provided 
sustained release of different drugs with varying solubilities in water and molecular 
weight.  Cubic phase has increased swelling capacity and high lipid loading capacity 
when compared with other dispersed or dispersible lipidic formulations.  Kossena et al. 
(2004) reported that in cubic phase an enhancement of greater than 2×10 5 fold over and 
above cinnarizine (a model poorly water-soluble compound) solubility in buffer 
(solubility in cubic phase, 53.1 ± 2.0 mg/ml; solubility in buffer, pH 6.5, 249.1 ± 9.2 
ng/ml, n=3) was seen and importantly, an increase in solubility above that in tricaprylin 
(a simple formulation TG, solubility 35.0 ± 0.5 mg/ml) was also evident.  
 
Cubic phases have been shown to deliver small molecule drugs and large proteins by oral 
and parenteral routes as well as local delivery in vaginal and periodontal cavity.  Using 
cinnarizine as the model drug, Kossena et al. (2004) investigated the intraduodenal 
administration of cinnarizine loaded into performed cubic phase comprising a monolaurin 
/ lauric acid mixture, resulted in a slow release in the concentration of cinnarizine in 
plasma compared to a suspension formulation.  A number of different proteins in cubic 
phase appear to retain their native conformation and bioactivityand are protected from 
chemical and physical inactivation perhaps due to the reduced activity of water and 
biomembrane-like structure of cubic phase.  Sadhale and Shah (1998, 1999) showed that 
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liquid crystalline cubic phase protected peptide-like insulin from agitation-induced 
aggregation and the peptide was biologically active in the cubic gel.  They also showed 
that cubic phase enhanced chemical stability of drugs like cefazolin and cefuroxime. 
 
Liquid crystalline phases can be produced using precursor, which can undergo 
transformation into cubic phase in situ.  Engstrom et al. (1992) used lamellar phase 
precursorwhich transformed into cubic phase and sustained the release of variety of drugs 
in situ. Kumar et al. (2004) demonstrated application of GMO matrix in floating drug 
delivery system, which also formed cubic phase in situ.  In situ transformation into cubic 
phase proceeds through a low-viscosity lamellar phase.  The lamellar phase is less 
efficient in controlling drug release and protection by immobilization of the drug-like 
peptides.  
 
Release of drugs from cubic phase typically show diffusion controlled release from a 
matrix as indicated by Higuchi’s square root of time release kinetics.  Incorporation of 
drug in cubic phase can cause phase transformation to lamellar or reversed hexagonal 
phase depending on the polarity and concentration of the drug, which may affect the 
release profile.  
 
3.2.2.1 Glyceryl monooleate (GMO)-water system 
Glyceryl monooleate (GMO), an amphiphilic lipid, forms various liquid crystalline 
phases in contact with water.  With regard to drug delivery, most of the work has been 
dedicated to the cubic phase based on GMO.  GMO is a common food additive and 
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pharmaceutical excipient (Rowe et al., 2003) that has been shown previously to enhance 
the bioavailability of co-administered poorly water-soluble drugs (Charman et al., 1993). 
Acyclovir can be incorporated into the cubic phase of glyceryl monooleate (GMO) and 
water (65:35% w/w) in relatively high concentrations (~ 40 % w/w) without causing any 
phase transition, which may be due to the relatively low solubility of acyclovir in the 
cubic phase (~ 0.1% w/w).  The rate-limiting step in the release process is most likely 
diffusion because the dissolution rate is of minor significance in the release process, 
which was further supported by identical release data obtained for micronized and 
nonmicronized acyclovir (Helledi et al, 2001).  
 
The drug delivery effectiveness of a binary GMO-water liquid crystalline phase 
composition is partly determined by the weight ratio of GMO to water.  Binary liquid 
crystalline phase systems are categorized as having either relatively high or low water 
content.  A “high water content” binary GMO-water composition having a weight ratio of 
from about 1:1 to about 4:1 GMO to water is well suited for delivering either water-
soluble or lipid-soluble drugs.  A “low water content” binary GMO-water composition 
having a weight ratio greater than about 4:1 GMO to water is well suited for delivering 
water-insoluble drugs.  A useful lipid crystalline phase drug delivery composition should 
be homogeneous.  A binary composition having a weight ratio less than about 1:1 GMO 
to water is not useful because it deleteriously separates into aqueous and liquid crystalline 
phases.  
 
3.2.2.2 Pluronic F127 system 
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One interesting cubic phase is that formed by the polyoxyethylene-polyoxypropylene co-
block polymer, pluronic F127.  This particularly attractive system has a high solubilizing 
capacity and is generally considered to be relatively non-toxic.  In aqueous solution, at 
concentrations greater than 20 % w/w, F127 is transformed upon heating from a low 
viscosity transparent (micellar) solution at room temperature to a solid clear gel (cubic 
phase) at body temperature.  Other members of the pluronic series also undergo a liquid 
to gel transformation at around body temperature, but only at higher surfactant 
concentrations (namely 30 % w/w and above) (Lawrence, 1994).  Esposito et al. (1996) 
reported pluronic based drug delivery system for intrapocket delivery. The formulations 
are easily administrated by syringe and becoming semisolid once in the periodontal 
pocket and finally, eliminated from the body by normal routes.  
 
3.2.2.3 Ringing gels 
Ringing gels with cubic liquid crystalline microstructure are marketed as commercial 
drug formulations especially for topical NSAID formulations.  Examples include 
Contrheuma Gel Forte N, Trauma-Dolgit Gel and Dolgit Mikrogel that are marketed in 
Germany.  The latter was introduced in 1996 and contains ibuprofen as the active 
ingredient.  On one hand, the high surfactant concentration of such gels is necessary to 
ensure the liquid crystalline microstructure but also to influence the microstructure of the 
stratum corneum lipids for increased permeability.  Increased permeability is also 
achieved by alcohol which is also solubilized in the formulation.  In permeation tests with 
excised human stratum corneum, the amount of ibuprofen permeating a specific surface 
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area over time was much higher for Dolgit Mikrogel than for an aqueous mixed micellar 
solution of the drug.  
 
3.2.2.4 Biosensor and biochips 
New applications of bicontinuous nanostructured cubic materials in biochip and 
biosensor technologies are being actively sought.  While lamellar bilayer-forming lipids 
are already used in biosensor systems, lipids forming non-lamellar structures, such as 
monoolein, are anticipated in novel protein biochip developments.  Furthermore, since 
cubic lipid phases are biocompatible and digestible, such bioadhesive matrices are being 
developed for controlled-release and delivery of proteins, vitamins and small drugs in 
pharmacological applications.  Another important application is that they offer a 3D lipid 
bilayer matrix for successful crystallization of membrane proteins. 
 
3.2.2.5 Cubic phase particles (Cubosomes) 
Cubosomes are submicron particles of bicontinuous cubic phases for lipophilic or 
amphiphilic active ingredient incorporation.  The surfactant assembles into bilayers that 
are twisted into a three dimension, periodic, minimal surface forming tightly packed 
structure like “honeycombed” with bicontinuous domains of water and lipid.  
 
Cubosomes address the varied challenges in oral delivery of numerous promising 
compounds including poor aqueous solubility, poor absorption, and large molecular size.   
Topical drug delivery systems are unique in situ forming bioadhesive LC systems that 
facilitate controlled and effective drug delivery to mucosal surfaces (buccal, ophthalmic, 
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vaginal and others).  This fascinating system forms a thin surface film at mucosal 
surfaces consisting of a liquid crystal matrix which nanostructure can be controlled to 
achieve an optimal delivery profile and provides good temporary protection of sore and 
sensitive skin.  Their unique solubilizing, encapsulating, transporting and protecting 
capacity are advantageously exploited in liquid and gel products used to increase 
transdermal and nasal bioavailability of small molecules and peptides.  Elyzol™ as an in 
situ forming liquid crystalline dispersion is commercially available.  
 
Commercial applications of cubosomes that are based on triglyceride-monoolein 
mixtures combined with the drug metronidazole have been developed to treat periodontal 
diseases.  The lipid-drug mixture forms a low-viscosity liquid that when applied to the 
gums and placed in contact with saliva, hydrates to form a bulk cubic phase that then 
delivers the drug to the gum.  
 
Compared to liposomes or vesicles, cubosomes possess much higher bilayer area-to-
particle volume ratios as well as higher viscous resistance to rupture.  Although bulk 
cubic phase has sufficient length scale to allow controlled release of solutes, cubosomes 
are too small and have too high a surface area for such performance, exhibiting instead 
burst release.  Other routes may still exist for controlled-release applications of 
cubosomes e.g. large poly (amidoamine) dendrimer molecules exhibit a 100× reduction 
in free diffusivity when entrapped in cubic phases.  
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The oral administration of drugs incorporated into dispersed liquid crystalline particles or 
cubosomes has also been reported.  Cyclosporine, a poorly water-soluble cyclic peptide, 
has been administered orally in cubic nanoparticles yielding improved bioavailability but 
not impacting significantly on time to reach peak concentration in plasma (Bojrup et al., 
1996).  Further, the oral administration of insulin loaded into GMO cubic phase particles 
provided a hypoglycaemic effect comparable to intravenous administration of insulin 
over a 6h period after oral administration (Chung et al., 2002).  
 
3.2.3 Smectic supercooled nanoparticles 
Kuntsche et al. (2004) reported that supercooled smectic cholesteryl myristate 
nanoparticles could be loaded with different model drugs without loss of the smectic state 
structure.  Drugs of lower melting points such as ibuprofen, etomidate and miconazole 
were incorporated in the dispersions at a concentration of 10 % w/w whereas 
progesterone with a higher melting point could only be dissolved in the lipid melt at a 
concentration of 1% w/w at appropriate dissolution times. 
 
In their further study, Kuntsche et al. (2008) studied the permeation of the model drug 
corticosterone using different lipid nanoparticles.  They reported that smectic 
nanoparticles seem to have no influence on the corticosterone permeation, and similar 
results were obtained for human and the cell culture epidermis.  Only cubic nanoparticles 
enhanced drug permeation distinctly and the enhancing effect was 7 fold higher in human 
epidermis than in the rat epidermal keratinocytes organotypic culture.  However, the 
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variation of the permeability coefficients was very high in human skin for smectic and 
cubic nanoparticles especially between the skin samples obtained from different donors.  
 
Table 3.2 Examples of drugs incorporated in smectic nanoparticles (Kuntsche et al. 2004) 
 Ibuprofen Etomidate Progesterone Miconazole 
Loading% 10 % 10 % 1% 10 % 
M.W. 206.28 244.29 314.46 416.13 
CLogP 3.72 ±0.23 2.32 ±0.75 4.04 ±0.28 5.93 ±0.56 














3.2.4 Liquid crystal-embedded membranes 
Lin et al (2000) demonstrated a thermo-responsive concept by embedding cholesteryl 
oleyl carbonate in cellulose nitrate membranes and showed temperature-induced on / off 
switching permeation of salbutamol sulphate.  The on-off thermo-responsive function of 
this liquid crystal-embedded membrane was conducted by altering the repeated 
temperature cycle between 10 and 25ºC, in which a cholesteryl oleyl carbonate with a 
phase transition temperature at 18ºC was used as a model of liquid crystal.  This system 















mixture of 36% cholesteryl oleyl carbonate (COC) and 64% cholesteryl nonanoate (CNN) 
in order to respond to skin temperature (i.e. 32ºC) of the human body (Lin et al, 2001). 
 
Rassoul Dinarvand et al (2006) investigated the use of thermotropic liquid crystalline 
(TLC) blends of 4-pentyl-4'-cyanobiphenyl (K15) and 4-heptyl-4’-cyanobiphenyl (K21) 
with appropriate nematic to isotropic phase temperature (Tn-i) just above body 
temperature as a temperature-modulated drug permeation system.  Paracetamol and 
methimazole were chosen as hydrophobic and hydrophilic drug models, respectively.  
Methimazole permeability through the TLC membrane was much higher (36.0×10-5 cm/s) 
at temperatures above the phase transition temperature of liquid crystal blends than that 
(7.2 × 10-5 cm/s) at temperatures below the phase transition temperature of liquid crystal 
blends (38.1ºC).  
 
3.3 Formulations / Uses of Liquid Crystals in Cosmetics 
Thermotropic liquid crystals are used in cosmetic formulations mainly for their striking 
visual effects.  They also offer an occlusive emolliency and can deliver small quantities 
of oil-soluble actives such as vitamins.  Because the iridescent colors of the liquid 
crystals are a consequence of the interaction of ambient light with the molecular 
arrangement of the materials, anything that disrupts the intermolecular structure will 
result in the loss of the colors.  Therefore, these materials must be used essentially “as is” 
and cannot be dissolved into or diluted by miscible solvents.  That said, small amounts 
(less than approximately 5%) of soluble substances such as fragrances, preservatives, and 
oil-soluble vitamins can be added as long as they do not interfere with the ordering of the 
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molecules.  The procedure for incorporating these materials is to heat the liquid crystal 
formulation until it becomes a clear isotropic liquid, adding the desired substance and 
mixing until dissolved and cooling back to room temperature in order to return to the 
liquid crystal state.  
 
The three main cosmetic applications of the materials are: 
1. In lip glosses.  The liquid crystals can be used as supplied as iridescent lip glosses.  
Dyes or pigments may be optionally added to give a large spectrum of colors 
ranging from light pastels for the un-pigmented materials to more intense shades 
in the colored products.  
2. In clear gels.  The liquid crystals can be incorporated as a swirl or ribbon into 
clear aqueous gels.  This results in a beautiful iridescent outcome that can easily 
be seen through the gel.  Care must be taken not to incorporate hydrophobic 
materials into the gel that can migrate into the liquid crystals and disrupt the 
molecular arrangement and eradiate the effect.  Liquid crystals may also be 
encapsulated into beads before addition to gels.  This isolates and protects the 
liquid crystals from the continuous phase and gives a different visual effect from 
the direct addition.  
3. In hair highlighters.  Application of the liquid crystal formulations to the hair, 












4.1.1 Differential scanning calorimetry (DSC) 
Phase transitions are accompanied by free energy changes, and are due to either an 
alteration in the enthalpy (∆H) or entropy (∆S) of the system.  Enthalpy changes result in 
either endothermic or exothermic signals, depending on whether the transition is due to 
consumption of energy, e.g. melting of a solid, or a release of energy, e.g. 
recrystallization of an isotropic melt.  Entropically caused phase transitions may be 
recognized by a change in baseline slope due to a change in the specific heat capacity. 
Liquid crystalline polymer phase transitions are entropically related and are thus 
considered second order transitions such as those from glass or rubber.  These are usually 
called glass transitions.  They may be accompanied by an enthalpic effect, therefore, 
complicating their detection (Müller-Goymann, 2004).   
 
It should be mentioned that the transition from the crystalline to amorphous phase 
requires a high energy input.  This is in contrast to crystalline to liquid crystalline and 
liquid crystalline to amorphous transitions as well as changes between different liquid 
crystalline phases, which all consume low amounts of energy.  Therefore care has to be 
taken to ensure that the measuring device is sensitive enough to give a sufficiently low 
detection limit.  
 
4.1.2 X-ray diffraction (XRD) 
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An intuitive understanding of x-ray diffraction can be obtained from the Bragg model of 
diffraction.  In this model, a given reflection is associated with a set of evenly spaced 
sheets running through the crystal, usually passing through the centers of the atoms of the 
crystal lattice.  The orientation of a particular set of sheets is identified by its three Miller 
indices (h, k, l), and let their spacing be noted by d.  X-rays scattered from adjacent 
planes will combine constructively (constructive interference) when the angle θ between 
the plane and the x-ray results in a path-length difference that is an integer multiple n of 
the x-ray wavelength λ. (Woolfson, M. 1997) 
 
According to Bragg’s equation, d can be calculated: 
   d= nλ/2sinθ 
Where λ is the wavelength of the x-ray being used, n is an integer and nominates the 
order of the interference, and θ is the angle under which the interference occurs 
(reflection conditions are fulfilled).  
 
From Bragg’s equation it can be seen that the interlayer spacing d is inversely 
proportional to the angle of reflection θ.  Large terms for d in the region of long-range 
order can be measured by small-angle x-ray diffraction (SAXD), while small terms for d 
in the region of short-range order can be investigated by wide-angle x-ray diffraction 
(WAXD).  
 
4.1.3 Determination of drug solubility in semisolids 
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Determination of drug solubility in semi-solids is problematic, therefore excess drug is 
added to produce a saturated system which is often wasteful and increases the cost of the 
formulation. Many methods have been used in attempts to measure solubility in semi-
solids and these include microscopic examination (Gopferich et al. 1992); conventional 
differential scanning calorimetry (DSC) (Jenquin et al. 1994; Theeuwes et al. 1974); 
HyperDSC (Gramaglia et al. 2005); infra-red attenuated total reflectance (IR-ATR) 
spectroscopy (Cantor et al. 1999); Higuchi release data (Chowhan et al. 1975) and x-ray 
powder diffraction (XRPD) (Suryanarayanan et al. 1992). Several methods were 
compared in measuring penciclovir solubility in films by Ahmed et al. (2004), and they 
found that visible microscopy was the simplest method to measure drug solubility 
although DSC, XRPD and release data provided additional information about release 
kinetics and drug characterization.  
 
4.2 Materials and Methods 
4.2.1 Materials 
The cholesteryl nonanoate (CNN), cholesteryl oleyl carbonate (COC) and cholesteryl 
chloride (CCL) were supplied by Hanhua Specialty Chemicals, China, and reportedly of 
98% pure.  The composition of blends was calculated on the assumption of absolute 
purity for the individual cholesteryl esters. Ibuprofen was from Sigma-Aldrich and used 






Chemical structures of cholesteryl esters and ibuprofen 
 









































4.2.2. Melting point detection 
The identity of cholesteryl esters were confirmed by detecting their melting point using a 
Gallenkamp melting point apparatus, and the results were in good agreement with the 





Melting point (ºC) and d001 spacing (Ǻ) data of cholesteryl esters and ibuprofen 
 
Melting point (ºC)  
M.P. apparatus DSC data Literature 
d001 spacing (Ǻ) 
(XRD data) 
CNN 77-78 77.29 70-80 14.418; 9.175; 5.066 
COC - 20.39 18 5.108 
CCL 96 95.87 ~100 5.65; 5.31; 4.47 
Ibuprofen  - 76 75 14.5; 7.2; 5.3; 4.7; 4.0 
 
 
4.2.3. Sample preparation 
The dispersions have traditionally been formed by heating mixes of the drug and carrier 
to the molten state (until it becomes a clear solution) followed by resolidification via 
cooling (under room temperature).  Alternative methods involve dissolving the 
components in a mutual volatile solvent followed by evaporation or dissolving the drug 
in a solvent such as chloroform and adding the resultant solution into the molten carrier.  
 
In the present study, each sample was prepared by heating cholesteryl nonanoate, 
cholesteryl oleyl carbonate and cholesteryl chloride, in a specific weight ratio, with the 
drug and mechanically stirring the mixture until the drug was completely dissolved to 
form a clear solution.  Next, the heated solution was cooled to room temperature, about 
24ºC.  The heating and cooling processes could be alternated several cycles until 
homogeneous samples were produced.  The concentrations of the incorporated drug were 
0.5, 1, 2 and 5 % (w/w).  The melting temperature was maintained at 85-95˚C. 
 
 39
4.2.4 Solubility and homogeneity determinations  
The solubility of ibuprofen in the liquid crystalline phase was determined by microscopic 
examination of the ibuprofen crystals at room temperature.  Ibuprofen-loaded cholesteryl 
esters were observed under a microscope at increased drug loadings (% w/w).  Solid 
crystals were observed with 11.4 % w/w ibuprofen load while no solid material was 
observed at 8.6 % w/w ibuprofen load.  As the drug loading increased, greater numbers of 
solid crystals were observed.  This suggested that the solubility of ibuprofen in the liquid 
crystalline matrix was between 8.6 % w/w and 11.4 % w/w. The homogeneity of the 
formulations was inspected visually under the microscope. 
 
4.2.5 Polarized light microscopy (PLM) 
The texture of the samples was observed using a polarizing light microscope (Olympus 
BX61, USA).  The measurements were carried out at room temperature, with a 100 x 
magnification.  
 
4.2.6 X-ray diffraction (XRD) 
X-ray diffraction (XRD) measurements were used to determine if the drug-free samples 
and drug-containing systems had organized structures.  The measurements were made 
using a Bruker-AXS D8 ADVANCE x-ray diffractometer (Germany).  The x-ray source 
tube was a copper anode emitting Kα rays at a wavelength of 1.5418Ǻ.  The samples were 
scanned from 2˚ to 60˚ (2θ) with a step size of 0.02˚ and a step interval of 1 s. XRD 
measurements were calibrated with corundum.  
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4.2.7 Differential scanning calorimetry (DSC)  
Thermal analyses were carried out by DSC (TA instrument 2920, U.S.A).  The 
temperature and heat flow calibrations were performed at a heating rate of 5˚C/min from 
-20 to 100˚C with indium (purity >99.999%) as a standard substance.  Liquid crystal 
samples, each accurately weight at around 5 mg, were analyzed at the same settings under 
a purge of nitrogen (40 ml/min).  Samples were weighed in DSC sample cups accurate to 
0.001 mg.  Each analysis was performed in triplicate.  
 
The 80/10/10 w/w/w samples loaded with and without 1% ibuprofen.  Each sample was 
treated through three cycles: (a) heated from -5ºC (after cooling from room temperature) 
to 100ºC, (b) cooled down from 100ºC to -5ºC and (c) heated again from -5ºC to 100ºC, 
to produce the DSC profile with a scan rate of 5ºC/min.  
 
4.2.8 Fourier transform infrared spectroscopy 
Fourier transform infrared (FT-IR) spectroscopy was employed to further investigate 
possible interactions between the drug and carrier matrices on a FT-IR spectrophotometer 
(Perkin-Elmer, Spectrum 100, USA) by the conventional KBr pellet method.  The spectra 
were scanned over a frequency range 4000-500 cm-1 with a resolution of 4 cm-1.   
 
 




Polarizing light microscopy revealed an anisotropic liquid crystal pattern with a 
characteristic ribbon structure as shown in Fig 4.1.  Ibuprofen showed birefringence 






Fig 4.1   Polarizing light microscopy of (a) liquid crystal matrix and (b) liquid crystal 




The liquid crystal mixtures, upon heating, lost their molecular orderliness and showed 
liquid crystalline phases.  The nematic-isotropic transition involves disrupting orientation, 
hence, is an endothermic process (Zou et al. 2004). As can be seen in Fig 4.2, phase 
transition temperatures varied almost linearly with the concentration (w/w) of COC or 
CNN.  The liquid crystal mixtures did not display three different phase transition 
temperatures attributed to the three cholesteryl esters separately.  They showed just one 
transition point, indicating that these esters had coalescent very well and behaved like a 
single pure material.  
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Dhar et al. (2002) observed the same behavior when the researchers used binary mixtures 
of heptyloxybenzoic acid and decyloxybenzoic acid in different mole ratios.  They 
showed that smectic to nematic and nematic to isotropic transition temperatures (Ts-n and 
Tn-i) vary, almost linearly, with the mole fraction of components, indicating the system as 
an ideal mixture.  Ng et al. (2001) adjusted the phase transition temperature of 
thermoresponsive membranes using appropriate molar ratios of two saturated straight 
chain alkanes, docosane (C20H42) and eicosane (C22H46) with melting points of 44.4ºC 
and 36.7ºC, respectively.  It was found that the phase transition temperature of the 
mixture varied with its composition and was directly proportiona to the ratio of the 
alkanes in the mixture.  
 
Therefore, by using the appropriate ratio of liquid crystal blends with different phase 
transition temperatures, it is possible to design a liquid crystalline system with a desired 
phase transition temperature, intermediate of the transition temperatures of component 
liquid crystals.  In the present study, three cholesteryl esters were mixed in different 
ratios and their different phase transition temperatures are shown in Table 4.3.  The 
CNN/COC/CCL (10/80/10, w/w/w) system was chosen for further study because it has a 
phase transition temperature which is near to body temperature.  
 
DSC thermographs of ibuprofen, liquid crystalline matrix (CNN/COC/CCL=10/80/10, 
w/w/w) and ibuprofen-loaded liquid crystalline matrix are shown in Fig 4.3 and Fig 4.4. 
The ibuprofen thermal curve shows a sharp endothermic peak at 76ºC and an enthalpy of 
around 150 J/g, representing its melting point (Fig 3.3) (Oladiran et al. 2007).  All 
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transitions were reversible upon cooling and reheating as shown in Fig 3.4.  Incorporation 
of the drug molecules did, however, influenced the liquid crystalline phase transition 
temperature, shifting to a lower temperature.  This could be explained by melting point 
depression due to “impurities” (Kuntsche et al. 2004).  However, due to the instrument 
monitoring lag, the transitions upon cooling were 1-2˚C lower than those observed upon 
heating.  As expected from the earlier reported work, the extent of this deviation was a 
function of heating and cooling rates (Galanti et al. 1972). 
 
The enthalpy value for each cycle of phase transition is around 1 J/g, which is in 
accordance with the literature that the smectic-cholesteric phase transition of COC has an 
enthalpy of 1.03 J/g, and the cholesteric-isotropic phase transition of COC has an 
enthalpy of 0.86 J/g (Lin et al. 2000).  
 
The DSC thermographs of ibuprofen-loaded liquid crystalline system (Fig. 4.4 B) showed 
no endothermic peak corresponding to ibuprofen.  Analogous phenomena have also 
previously been reported by various researchers (Ahuja et al. 2007; van den Mooter et al. 
1998; Damian et al. 2000; Guyot et al. 1995).  Compared to the DSC thermograph of the 
physical mixture of ibuprofen with liquid crystal blend (in which ibuprofen existed in a 
crystalline state), the latter had another smaller endothermic peak with the onset at around 
70ºC, which was related to the melting point of ibuprofen (data not shown here).  As the 
DSC method was based on the principle that the fraction of drug solubilised within the 
matrix did not contribute to the melting endotherm associated with the dispersed drug 
fraction, the non-appearance of the ibuprofen peak at around 70ºC that the drug 
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incorporated had dissolved in the molten carrier during the drug loading process.  
Victoria and David (2003) analyzed ethosuximide suppository formulations using DSC, 
they observed that at higher drug concentrations (>30 % w/w), a separate endothermic 
melting peak was observed for the drug indicating that it exceeded the solubility of the 
drug in the wax matrix. 
 
Table 4.3 

















(ºC, ± S.D.) 
100 0 0 20.0 ± 0.39 
0 100 0 77.3 ± 0.45 
0 0 100 95.9 ± 0.73 
34 56 10 63.3 ± 1.53 
40 50 10 59.6 ± 1.28 
42 28 30 51.8 ± 1.02 
45 35 20 62.8 ± 1.38 
70 20 10 42.1 ± 0.96 
70 15 15 40.7 ± 1.12 
70 10 20 39.7 ± 0.59 
75 10 15 38.0 ± 0.48 
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Fig 4.2   Plots of phase transition temperatures of mixed liquid crystalline systems as a 
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Fig 4.4   DSC heating and cooling curves (5ºC/min) of liquid crystalline matrices with 
and without ibuprofen loaded. The three cycles are noted as C1 (first heating), C2 
(cooling) and C3 (second heating). Systems are (A) liquid crystalline matrix 
(CNN/COC/CCL = 10/80/10, w/w/w); (B) liquid crystalline matrix (same as (A)) loaded 
with 1 %, w/w ibuprofen.   
 
 
The x-ray diffractograms of ibuprofen crystals, of liquid crystalline matrix 
(CNN/COC/CCL = 10/80/10, w/w/w) and liquid crystal impregnated with 1% w/w 
ibuprofen are displayed in Fig 4.5 and Fig 4.6.  X-ray diffraction pattern of ibuprofen 
(Fig 4.5) revealed high intensity reflections which corresponded to the following 
interplanar distances (d001): 14.5, 7.2, 5.3, 4.7, and 4.0 Ǻ with characteristic peaks at 6.1º 
(a) 12.2º (b) 16.6º (c) 19.0º (d) and 22.3º (e) (2θ), respectively (Mallick et al. 2008).  The 
liquid crystalline matrix showed peaks of high intensity at 17.6º (2θ) at 30ºC as well as at 
45ºC while the intensity decreased with the increased temperature (Fig 4.6 a, b).  After 
incorporation of ibuprofen into the liquid crystalline matrix, the peaks shifted to 18.02º 
(2θ) at the same temperature conditions of 30ºC and 45ºC (Fig 4.6 c, d).  This implies that 
liquid crystalline samples containing ibuprofen also retained their organized structure.  
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According to Bragg’s law, the higher shift of peaks corresponded to a decrease in 
interplanar distance, which decreased from 5.03Ǻ to 4.91Ǻ.  This might be influenced by 
the incorporation and distribution of ibuprofen molecules in the liquid crystalline 
structure of the matrix.  Makai et al. (2003) reported that there was a further increase in 
the dL values after incorporation of tenoxicam and ephedrine hydrochloride, from which 
it could be concluded that the drugs were located  partly into the lamellar spaces and 
partly at the given polarity part of the amphiphilic surfactant molecules.  
 
It was also observed that the ibuprofen sample lost its crystalline signature after loading 
into the liquid crystalline matrix, comparing Fig 4.5 with Fig 4.6.  In the ibuprofen-
loaded liquid crystalline samples, the lack of diffraction peaks of ibuprofen indicated that 
no re-crystallization occurred in the liquid crystalline matrix when cooled after loading in 
the ibuprofen with the aid of heat.  Thus, the incorporated ibuprofen molecules were 
entrapped with the liquid crystalline structure, thus showing the appearance of a 
molecularly amorphous state.  When heated during the process of drug loading, the 
temperature was sufficiently high enough to melt the ibuprofen crystals as the drug has a 
relatively low melting point, of around 75ºC (Fig 4.3).  Charnay et al. (2004) also 
reported that ibuprofen was entrapped into the pores of templated mesoporous silica 
(MCM 41) and appeared in an amorphous state.  This is in agreement with a 
crystallization study carried in confined space by Sliwinska-Bartkowiak et al. (2004) that 
showed crystallization occurred only when the channel pore size was significantly larger 





















Fig 4.5   XRD pattern of ibuprofen with characteristic peaks at (a) 6.1º; (b)12.2º; (c) 16.6º; 
























Fig 4.6   XRD pattern of liquid crystal (LC; CNN/COC/CCL=10/80/10, w/w/w) with and 
without ibuprofen at the concentration of 1% w/w at different temperatures below and 
above phase transition temperature: (a) LC, 30ºC, 17.6º (2θ); (b) LC, 45ºC, 17.6º (2θ); (c) 




Fig 4.7 shows the FTIR spectra of the drug (A), liquid crystal carrier (B), drug-embedded 
matrices ((C) and (D)) and the corresponding physical mixtures ((E) and (F)).  The 
characteristic peaks for ibuprofen (in KBr): 1720 cm-1 for C=O stretching, 2955 cm-1 for 
bonded O-H stretching (Maheshwari et al., 2003).  As for the liquid crystal carrier, the 
peaks at 1739 or 1736 cm-1 were assigned to the carbonyl stretching of ester, the peaks at 
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1466 and 1377cm-1 were due to the CH2 and CH3 bending vibrations, the peaks around 
1265-1255 or 1171 cm-1 corresponded to the methylene wagging, twisting vibrations 
and/or also to the ester C-O stretching mode for COC and CNN, respectively (Pavia et al., 
1979; Pretsch et al., 1989).  The peaks at 2927, 1743 and 1252cm-1 for COC were 
assigned to the asymmetric CH2 stretching, carbonyl stretching, and the methylene 
wagging and twisting vibrations and/or C-O stretching mode of the carbonate, 
respectively.  The peaks at 2933, 1736, and 1171cm-1 for CNN correspond to the similar 
assignments of COC (Lin et al., 2001).  
 
The absence of shifts in the wavenumbers of the FTIR peaks of the liquid crystalline 
matrix vis-à-vis the physical mixture indicated the lack of significant hydrogen bonding 
interactions between the drug and the liquid crystal in the liquid crystalline dispersion.  
Similar FTIR results have also been reported (Ahuja et al., 2007).  Interactions between 
the incorporated drug and the carrier based on FTIR studies were reported as well. 
Mallick et al. (2008) reported an acid-base reaction between the carboxylic acid 
containing ibuprofen and Al2O3 of kaolin to form its salt.  FTIR spectra showed the free 
acid carboxyl peak and the drug dimmer or oligomeric peaks disappeared and the peak 
for the carboxylate ion appeared.  Electrostatic forces (between COO- and counter ion 
Al3+) and hydrogen bonding interactions appeared to drive the amorphization of the drug 
in the matrix.  Karavas et al. (2007) reported an NH-O hydrogen bond was formed 
between felodipine and polymers (PVP or PEG) as indicated by FTIR data.  The 
interactions of felodipine with the polymer molecules appeared to control the physical 
state (amorphous or crystalline) and the particle size of felodipine in the solid dispersions.  
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Fig 4.7   FT-IR spectra of ibuprofen (A); liquid crystal carrier 
(CNN/COC/CCL=10/80/10, w/w/w) (B); liquid crystal carrier (same as (B)) loaded with 
1 % ibuprofen (w/w) (C); liquid crystal carrier (same as (B)) loaded with 10 % ibuprofen 
(w/w) (D); physical mixture of liquid crystal carrier (same as (B)) with 10 % ibuprofen 
(w/w) (E); physical mixture of liquid crystal carrier (same as (B)) with 20 % ibuprofen 




An interaction between the drug and the liquid crystalline system could result in the 
precipitation of drug crystals into the system and subsequent instability (Burrows et al., 
1994).  Thus, it was important to ensure that the appropriate level of drug loading was 
used to avoid subsequent  re-crystallization upon storage. 
 
After storing a 5 % (w/w) drug loaded liquid crystalline sample for 2 days, white needle-
like ibuprofen crystals were observed to have precipitated when observed under 
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microscope.  The amorphous drug that remained stabilized at 1 % (w/w) drug loadingin 
the liquid crystalline matrix was the result of the physical presence of cholesteryl ester 
chains and van de Waals or dipole-dipole hydrophobic interactions. During the heat-aided 
drug loading process, drug molecules were brought beyond the melting point, and a phase 
change to the liquid form helped drug molecules to break away and become inserted into 
the “solubilising cavities” of the liquid crystalline matrix, thereby establishing bonds with 
the molecules of the matrix.  When the drug incorporated is in excess, although appearing 
as an amorphous state immediately after preparation, the excess will eventually 
crystallize out, leaving a more thermodynamically stable and organized liquid crystal 
dispersion and drug crystals.  Re-crystallization of amorphous drug from the matrix is 




The results obtained showed that ibuprofen could be loaded into the liquid crystalline 
structures of cholesteryl esters.  The presence of organized liquid crystalline structures 
was confirmed by polarizing light microscopy and x-ray diffraction, and the structures 
were shown to remain relatively unchanged after drug loading.  These mixtures behaved 
exactly like pure liquid crystals as they showed single temperature for each phase 
transition.  The inclusion drug molecules remained in a molecularly distributed 
amorphous state as no crystalline drug evidence was found in the matrix as shown by 
DSC and x-ray diffraction studies.  FTIR spectra revealed absence of hydrogen bonding 
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interaction within the liquid crystalline matrix.  It was probably van de Waals or dipole-























CHAPTER 5 IN VITRO DRUG RELEASE STUDY 
 
 
5.1. Introduction  
5.1.1 In vitro release test apparatus 
The SUPAC-SS guidelines list two requirements for an in vitro release test for semisolids. 
First, “sink condition” must be maintained.  This can be achieved by ensuring that the 
drug has sufficient solubility in the receptor medium such that the receptor medium does 
not hinder the release rate of the drug.  This will presumably occurs if the concentration 
of drug in the receptor phase,  ≤ 10 % of the saturation solubility of the drug in the 
receptor medium, , i.e., C
tC
srC t ≤ 0.1Csr.  A second requirement for an in vitro release test 
for semisolids is that the percentage of drug released is less than 30 % of the drug placed 
in the donor compartment (Rapedius et al., 2001).   
 
In a typical procedure, a thin film (finite) or relatively thick (infinite) dose of formulation 
is applied to the surface of the membrane mounted in a Franz diffusion cell (Fig 5.1) and 
the rate of appearance of active in the receptor phase is equated with the rate of release 
from the formulation (Piemi et al., 1998; Stinecipher and Shah, 1998).  In some cases, the 
use of a membrane is to act solely as a support to keep test formulation and receptor 
phases as separate entities throughout the experimental period; whereas measurement of 
diffusion through the membrane is the objective in other cases (Gallagher et al., 2003).  
 
For products containing water-insoluble drugs, selection of an appropriate receptor 
medium to maintain sink condition during in vitro release studies can be a challenge.  The 
achievement of drug release from such topical preparations can be carried out with 
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receptor media containing surfactants and different organic / aqueous solvents.  Use of 
surfactants had caused foaming and formation of air bubbles during receptor mixing and 
the presence of air bubbles could diminish the contact area between the receptor medium 
and the supporting membrane (Shah et al., 1999). 
 
Sometimes, it is possible to study the release of drugs from ointments into aqueous media 
in the absence of a separating membrane.  The release rates of betamethasone 
dipropionate, fluocinonide and clobetasol propionate from ointments were found to be 
equivalent with and without interposed membranes, establishing that the membranes used 
in studying release functioned solely as supportive structures (Shah et al., 1995).  Creams 
and gels invariably may contain phases and adjuvant components which are watery, 
water miscible or water soluble.  A membrane must be placed between such donors and 
the receptor to maintain their physical integrities.  Membranes are selected for use which 
are commercially available (the practical way to assure reproducible membrane 
properties over time), have little capacity to bind the drug, have little tendency to interact 
with the releasing medium, and offer the least possible diffusional resistance.  The 
inertness and low diffusional resistance of polysulfone membranes have favored their use 
in the U.S. Food and Drug Agency’s laboratories.  Other membranes, such as nylon, 
cellulose nitrate and cellulose acetate have also been employed successfully (Flynn et al., 
1999).   
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Fig 5.1   Design of the vertical Franz diffusion cell used in the Microette and 
MicroettePlus system (Shah et al., 2003).  
 
 
5.1.2 Drug release theory 
Many controlled-release products are designed on the principle of embedding the drug in 
a porous matrix.  Liquid penetrates the matrix and dissolves the drug, which then diffuses 
into the exterior liquid (Fessi et al., 1982).  Wiegand and Taylor (1959) and Wagner 
(1959) showed that the percentage of drug released versus time profiles for many 
controlled release preparations reported in the literature showed a linear apparent first-
order rate.  Higuchi (1961, 1963) tried to relate the drug release rate to the physical 
constants based on simple laws of diffusion.  Release rates from both a planar surface and 
a sphere were considered. The analysis suggested that in the case of spherical pellets, the 
time required to release 50 % of the drug was normally expected to be 10 % of the time 
required to dissolve the last trace of solid drug in the centre of the pellet.  
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Higuchi (1967) was the first to derive an equation to describe the release of a drug from 
an insoluble matrix as the square root of a time-dependent process based on Fickian 
diffusion.  Mathematically this is represented by the following equations.   
For a suspension:  
( )[ ] 212 tCCADQ ss−=                                                                                                     (5.1) 





DtAQ                                                                                                                 (5.2) 
where Q is the amount of drug released after time, t is the drug release duration, D is the 
diffusivity of the drug within the matrix, A is the initial total drug concentration, and Cs is 
the drug solubility within the matrix.  Both equations describe drug release as being 
linear with the square root of time:  
21tkQ H=                         (5.3) 
where kH is the release rate constant, the slope of a plot of Q versus t1/2; although this 
value differs according to whether the drug is in suspension or solution.  
 
According to Higuchi, the equation is valid if: (a) the percent released is <30 % of the 
total drug in the vehicle, (b) a single drug species is present in the vehicle, (c) the 
diffusion coefficient of the drug remains the same with respect to both time and position 
in the vehicle layer, (d) components of the vehicle do not diffuse out, and (e) the drug 
reaching the receptor side is removed rapidly (Chi et al., 1991).   
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The drug release models tested in the present study are described below (Equation 5.4-
5.8).  They include: 
zero-order release kinetics 
11 ctkF +=                                                                                                                  (5.4), 
first-order release kinetics 
221 ctkeF +−=−                                                                                                              (5.5), 
square root of time release kinetics 
3
2/1
3 ctkF +=                                                                                                             (5.6), 
Higuchi spherical matrix release kinetics / Baker-Lonsdale model 
( )[ ] 443/21123 ctkFF +=−−−                                                                                    (5.7), 
and, Hixson-Crowell cube root model 
( ) tkF 53/1 11 −=−                                                                                                       (5.8), 




5.2 Materials and Methods 
5.2.1 Franz diffusion cell system 
In vitro release for liquid crystal products were carried out using a vertical diffusion cell 
system (Microette with automated sampling, Hanson Research Corporation, USA) and a 
synthetic support membrane (polycarbonate, Millipore, pore size 0.2 μm and diameter 47 
mm).  The 1.5 ml of the viscous ibuprofen-containing liquid crystal were syringed into 
the dosage wafer on top of the membrane and covered with glass disks.  The receptor 
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medium was phosphate-buffered saline (PBS, constituents per L were 2.38 g Na2HPO4, 
0.190 g H2KPO4, 8.00 g NaCl, 3 mM NaN3; pH 7.4).  Samples (0.5 ml) were withdrawn 
at predetermined time intervals (0.5, 1, 2, 4 and 6 h).  Equal volumes of fresh dissolution 
medium, maintained at the same temperature, were added after withdrawing the samples 
to maintain the recipient volumes.  Percentages of drug dissolved at different time 
intervals were calculated based on values obtained using the equation generated from the 
standard curve.  
 
5.2.2 Sample analysis 
Reversed-phase high-performance liquid chromatography (HPLC) equipped with a 
Hypersil BDS (150×3 mm, particle size 3 μm) column was employed in ibuprofen 
content analysis.  A mobile phase of acetonitrile / water (60:40, v/v, pH = 4.2) was 
pumped at 0.3 ml/min through the column for the analysis.  The samples were filtered 
through 0.2 μm membranes (RC, pore size, Ø 4 mm, Sartorius) before injection into 
HPLC by the auto-injector.  
 
5.2.3 Release rate determination  
The measured ibuprofen concentration in the receptor medium was first corrected for the 
replaced sample volume and dilution cycles using the method described previously by 














where is the expected concentration of the nth sample if previous samples had not been 
removed, is the measured concentration of the nth sample, is the uncorrected 
concentration of previous sample, X is the sample volume collected for assay, 7mL is the 
volume of the receptor compartment and the ∑ term represents the sum of uncorrected 
concentrations of prior sampling from the first sample to the sample immediately before 







5.2.4 Dissolution data analysis 
The dissolution data obtained was fitted to various mathematical models corresponding to 
possible release mechanisms.  In order to discriminate any two release profiles, a two-
way ANOVA was performed using GraphPad PRISM® version 5.0 from GraphPad 
Software Inc.(California, USA).  In this test, p<0.05 indicated that any two release 
profiles were statistically significantly different and p>0.05 indicated the similarity 
between the two release profiles.  The release profiles were also compared pair-wise 















where Rt and Tt are the cumulative percent releases at time t, for any two release profiles. 
The value of f2 ranges from 0 to 100 with a higher f2 value indicating more similarity 
between the two profiles.  It was observed that release profiles with f2 values between 65 
and 100 correlated well with the release profiles having p values greater than 0.05 (Table 
5.1) (Shah et al., 1998; Cheboyina et al., 2008).  Therefore, in this study, any two release 
profiles were considered similar if the f2 values were between 65 and 100.  
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 Table 5.1   Average difference between two dissolution profiles of reference batches 
(Shah et al, 1998) 
 
 2% 5% 10 % 15% 20 % 





5.3 Experimental Results  
 
5.3.1 Influence of temperature 
 
The release profiles of ibuprofen from the liquid crystalline matrix (CNN/COC/CCL 
=10/80/10, w/w/w) at different temperatures are shown in Fig.5.2 and Fig. 5.3.  The 
phase transition temperature of this liquid crystal system is around 34-35ºC, which can be 
seen from DSC data (Fig. 3.4).  From the release profiles in Fig. 5.2, it was observed that 
the release rate and amount of ibuprofen increased significantly from 34ºC to 44ºC 
(p<0.05) at drug loadings of 0.5%, 1% and 2%.  However, there are no significant 
differences for the release profiles of 1%ibuprofen released from this liquid crystalline 
system between 30ºC and 34ºC (p>0.05), as well as between 44ºC and 49ºC (p>0.05) as 
can be seen from Fig 5.3.  
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Fig 5.2   Cumulative amount of ibuprofen released per unit surface area from the liquid 
crystalline matrix (CNN/COC/CCL=10/80/10, w/w/w) at different temperatures below 
and above the phase transition temperature of the liquid crystal blends at drug loadings of 
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Fig 5.3   Cumulative amount of ibuprofen released per unit surface area from the liquid 
crystalline matrix (CNN/COC/CCL=10/80/10, w/w/w) at different temperatures below 
and above the phase transition temperature of the liquid crystal blends at drug loading of 




This marked increase in drug release might be caused by activation of thermal molecular 
motion of liquid crystal and / or an enhancement of pore formation around the domain of 
liquid crystal (Kajiyama et al., 1982; Washizu et al., 1984; Lin et al., 2002).  This implies 
that the liquid crystalline system studied here had a thermo-responsive property.  Similar 
results have been reported by Dinarvand et al. (2006) and it showed that the permeation 
of mathimazole and paracetamol through liquid crystal-embedded membrane were 
statistically significantly different below and above phase transition temperature.  
 
The diffusion coefficients (D) of ibuprofen were calculated from the slope of the Higuchi 
plots according to Equation 5.2.  It was found that D increased when the temperature was 
raised from 34ºC to 44ºC.  Chi et al. (1991) reported that the diffusion coefficients of 
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ketoprofen increased approximately threefold when the temperature was raised from 25 
to 45ºC, despite the increased viscosity of the gel at higher temperatures.  The increased 
diffusion coefficient resulted in increased amount of drug release.  
 
5.3.2 Influence of initial drug loading 
 
Fig 5.4 shows the cumulative amount of drug released per unit surface area from the 
liquid crystalline system, as a function of time.  Several selected initial drug loading 
concentrations were attempted.  It can be seen from Fig 5.4 and Fig 5.5 that the increase 
in initial drug loading concentration led to an increase in the rate and amount of drug 
released.  Fig 5.5 shows that the gradients of plots of amount released as a function of the 
square root of time for ibuprofen increased almost by a factor of 2.77 as the initial drug 




































Fig 5.4   Cumulative amount of ibuprofen released per unit surface area as a function of 
time from the liquid crystalline matrix (CNN/COC/CCL=10/80/10, w/w/w) at the 
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Fig 5.5   Plot of release rate, as a function of initial ibuprofen loading at the temperature 





Fig 5.6 represents drug release data expressed as a percentage base.  The ibuprofen 
released as a function of time from the matrix with initial drug loading between 0.5 and 5 
% (w/w) were similar for all the samples studied, indicating that the fractions of drug 
released or the release kinetics were independent of the initial drug loadings used 
(p>0.05).  Similar results were reported for oxibutinin (Geraghty et al., 1996), 
pseudoephedrine hydrochloride (Chang and Bodmeier, 1997a), and salicylic acid (Lara et 
al., 2005) in vitro release.  The solubility and concentration of the incorporated drug 
influences the release profile from the GMO / water system according to Norling et al. 






























Fig 5.6   Plots of the percent released of ibuprofen from the liquid crystalline matrix 
(CNN/COC/CCL =10/80/10, w/w/w) at drug loadings of 0.5, 1, 2 and 5 % at 34ºC (n=3, 
±S.D.) 
 
5.3.3 Influence of liquid crystal structure  
Fig 5.7(A) shows the in vitro release profiles of 1 % ibuprofen from liquid crystalline 
matrices of different mixing ratios at the temperature of 44ºC.  As can be seen from the 
XRD data (Fig 5.7 B), the 56/34/10 (w/w/w) mixture showed much more crystallinity 
character than the 80/10/10 (w/w/w) mixture because of a higher phase transition 
temperature (around 60ºC, Table 4.3).  As a result of the much more ordered structure, 
the viscosity of 56/34/10 (w/w/w) mixture was higher than 80/10/10 (w/w/w) mixture at 







where D is the diffusion coefficient (cm2/s), κ  is Boltzmann’s constant (J / ºK), T is the 
absolute temperature (ºK), η  is the viscosity (Ns/m2) and r is the radius (m) of the 
diffusing molecule.  The increase of η is associated with the decrease of D, which is the 
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diffusivity of the drug molecule.  This could explain why ibuprofen released from 
56/34/10 (w/w/w) mixture matrix was slower than that from 80/10/10 (w/w/w) matrix. 
Farkas et al. (2007) also reported that as a result of the changes of liquid crystalline 
structures, the drug release of various types of chlorhexidine could be modified.  The 
isotropic and less ordered structure allowed more chlorhexidine base to be released from 
the liquid crystals compared to the more viscous system containing ordered hexagonal 
structural elements.  In all these cases, drug release was governed mainly by the structure 
of the liquid crystal, and the extent of drug release was in accordance with the viscosity 
of the systems.    
 
5.3.4 Influence of physical state of drug in the matrix  
Mallick et al. (2008) reported that for in vitro dissolution studies, an increase for 
ibuprofen in amorphous state was obtained compared to crystalline ibuprofen from kaolin 
co-milled powders.  This could be attributed to the corresponding reduced ordering of 
crystal lattice.  Gamma polymorphs of indomethacin had been transformed to amorphous 
state by milling and this amorphous state showed 60 % higher solubility than the 
crystalline state (Otsuka et al., 1986).   
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Fig 5.7   Comparison between two liquid crystalline systems (a) 
CNN/COC/CCL=10/80/10, w/w/w; (b) CNN/COC/CCL=56/34/10, w/w/w : (A) 
cumulative amount of ibuprofen released per unit surface area as a function of square root 
of time at the temperature of 44ºC from (a) and (b); (B) XRD patterns of system (a) and 







5.3.5 Evaluation of drug release mechanism  
Release data obtained from in vitro release tests were fitted to various mathematical 
models corresponding to possible release mechanisms (Equation 5.4-5.8).  Linear 
regression analyses of each profile were performed and the respective rates of release 
determined from the slopes of the lines.  The goodness of fit (r2) values for the various 
models are given in Table 5.3.  All the release profiles were found to be statistically 
significantly different from each other (p<0.05), and f2 values are given in Table 5.2 
(0<f2<65).  
 
Table 5.2  
Similarity factor (f2) 
 
DL* / T** 2f value 
0.5% 34ºC vs. 1% 34ºC 43.75 
1% 34ºC vs. 2% 34ºC 30.07 
2% 34ºC vs. 5% 34ºC 1.58 
0.5% 34ºC vs. 0.5% 44ºC 59.49 
1% 34ºC vs. 1% 44ºC 53.63 
2% 34ºC vs. 2% 44ºC 51.45 




F-test used to compare the models indicated that the release data from the liquid crystal 
matrix at the initial drug loadings studied, below and above the phase transition 
temperature fitted very closely to square root Higuchi release model (Gohel et al., 2000; 
Cheboyina et al., 2008).  Therefore, the drug release obtained for the liquid crystalline 
matrices followed a Fickian diffusion mechanism.  
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 Table 5.3  













DL* / T**  r2
0.5 % 34ºC 0.9921 0.9919 0.99 0.9555 0.893 
1.0 % 34ºC 0.9948 0.957 0.9558 0.9787 0.9404 
2.0 % 34ºC 0.9941 0.9937 0.9929 0.9848 0.949 
5.0 % 34ºC 0.9961 0.9595 0.9568 0.9896 0.8736 
0.5 % 44ºC 0.9946 0.9876 0.9855 0.9852 0.9318 
1.0 % 44ºC 0.9943 0.9909 0.9895 0.985 0.9416 
2.0 % 44ºC 0.9989 0.9809 0.9789 0.9869 0.9166 




In order to distinguish between diffusion-controlled and first order models, the data were 
also analyzed by the method proposed by Schwartz et al. (1968), which had been used by 
Burrows et al. (1994), Geraghty et al. (1996) and Lara et al.(2005).  The release rate was 
found to be proportional to the amount of drug released by first-order kinetics but 
proportional to the reciprocal of the amount of drug released for the diffusion model.  The 
plots of release rate (μg/hr) as a function of the release amount (μg) as well as the 
reciprocal of the release amount (μg-1), for a liquid crystalline system (CNN/COC/CCL 
=10/80/10, w/w/w) loaded with 2% w/w ibuprofen at 34ºC, are shown in Fig 5.8.  A 
straight line (r2 = 0.989) was obtained by plotting the rate of release (μg/h) as a function 
of the reciprocal of the amount of drug released (μg-1), confirming that the ibuprofen 



















































Fig 5.8   Plots of the rate of ibuprofen released from liquid crystalline system 
(CNN/COC/CCL =10/80/10, w/w/w) at drug loading of 2% w/w at 34ºC as a function of: 
(A) 1/ (amount of drug released) and (B) amount of drug released.  The rates values were 






In the release plots showing the amount of drug released vs. square root of time, an x-
intercept was observed.  This x-intercept is a common characteristic of an in vitro release 
test and is referred to as the “lag time” (tlag).  This value should normally correspond to 
only a small fraction of an hour.  The mean lag time in this present study was found to be 
5.5 minutes.  The value was not significantly different from “0” (p>0.05), and was less 
than 10 % of the total run time, which was 360 minutes.  The presence of the lag time 
indicated that the release of ibuprofen from the matrix did not occur instantaneously, and 
the release pattern only became linear until after the first sampling time point, at 30 
minutes.  The lag time resulted from using pre-hydrated membranes also implied that this 
membrane did not constitute a rate-limiting barrier for the release process.  
 
There are possibly three steps which govern the drug release from the matrix: penetration 
of the dissolution medium into the matrix, dissolution of dispersed drug particles and 
diffusion of the dissolved drug through the matrix.  The slowest step will control the 
overall drug release rate.  If the diffusion of the drug is the rate-limiting step, the drug 
release will likely to follow Higuchi square root kinetics.  However, if the dissolution of 
the drug is the rate-limiting step, the drug release follows zero-order kinetics 
(Chandrasekaran, et al., 1982; Chang et al., 1990).  
 
The release rate of a drug is controlled by a number of factors related to both the drug and 
the matrix itself.  The diffusion coefficient (D) of the drug is dependent on its 
hydrodynamic radius (r), i.e. largely on its molecular weight and wetting characteristics. 
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Generally, the smaller the drug molecule, the faster is the release rate and the larger is D. 
In the case of small molecules such as rubipy, tryptophan and to some extent, the 10-mer 
DNA linker, release from the cubic phase occurred over a period of 1-3 days.  For 
intermediate sized molecules, such as cytochrome c, lysozyme and myoglobin, the bulk 
of the release happened over a week (Lopes et al. 2007).  
 
Release rates have been related to the solubility of the drugs in the liquid crystalline 
systems (Burrows et al., 1994).  In cases where a fraction of the drug, small or large 
molecular size, is present as suspended matter, the solubility of the drug sets the 
steepness of the operative concentration gradient across the receding boundary.  When 
the physical drug particles are completely dissolved, the bulk phase drug concentration 
determines the gradient’s steepness.  The gradient ebbs and thus release rate slows down 
as the release study progresses (Flynn et al., 1999). 
 
Interactions of a hydrophilic drug with the lipid matrix by, for example, hydrogen 
bonding or ion-pairing, may also alter the release rates by reducing the diffusion 
coefficients.  If a drug is transported primarily through the aqueous domain of the matrix, 
then the access of the aqueous domain to the external aqueous solution is likely to be an 
important factor governing drug escape from the matrix.  A more rapid release of a drug 
from cubic phase compared to hexagonal phase can be attributed to the differences 





In diffusion-controlled systems, as the drug loading increases, cavities resulting from the 
dissolution of drug provide extended pathways for the escape of the residual drug within 
the system.  These cavities increase the overall apparent permeability of the drug 
resulting in higher release rates.  For a three-dimensional matrix, the critical drug loading 
above which a continuous network of pathways form is only about 15 %, v/v (Zaller, 
1977).   
 
The drug release also depended on the method employed to determine the amount of drug 
released.  Lee et al. (2000) reported that the release profiles obtained by the Franz cell 
method were much slower than the immersion method due to the membrane restricting 




The Higuchi release model most aptly fitted the in vitro release profile of ibuprofen from 
a liquid crystalline matrix system.  Therefore, the drug release rates from the liquid 
crystalline matrices were controlled predominantly by Fickian diffusion.  Drug release 
was influenced by phase transition of the matrix, initial drug loading, as well as the 








CHAPTER 6 SUMMARY AND FUTURE DIRECTIONS 
 
The present study has investigated the in vitro ibuprofen release profiles from a liquid 
crystalline system with a combination ratio of CNN/COC/CCL=10/80/10 w/w/w.  The 
presence of organized liquid crystalline structures was confirmed by polarizing light 
microscopy and x-ray diffraction, and the structures were shown to remain relatively 
unchanged after drug loading.  The inclusion drug molecules remained in a molecularly 
distributed amorphous state as no crystalline drug evidence was found in the matrix as 
shown by DSC and x-ray diffraction studies.  Drug-carrier interactions were probably van 
de Waals or dipole-dipole interactions because FTIR spectra revealed absence of 
hydrogen bonding interaction within the liquid crystalline matrix.  The in vitro ibuprofen 
release profiles most aptly fitted the square root Higuchi release model, indicating that 
drug release was predominantly controlled by Fickian diffusion.  Drug release was 
influenced by the phase transition of the liquid crystalline matrix, initial drug loading, as 
well as the viscosity of the matrix system.  
 
The present study was limited to one hydrophobic drug and one type of combination 
ratios of the liquid crystal components.  Further work can be done using drugs of various 
hydrophobicity and different types of cholesteryl esters, e.g. cholesteryl myristate, 
cholesteryl linoleate, in order to get a comprehensive understanding of applications of 
cholesteryl esters. It is also very promising to use cholesteryl ester systems to stabilize 




In addition, investigation of the drug release profiles influenced by the physical state of 
drug in the liquid crystalline matrix, i.e. whether the drug is in an amorphous or a 
crystalline state, would provide additional information.  Moreover, experiments should be 
conducted to study drug release within a longer time range and get the release profile at 
time intervals of 12hours, 24 hours, 48 hours or even longer.  Further efforts should also 
be made to investigate if drug solubility in the matrix would influence the drug release 
profile, and in this regard, drug localization in the matrix would be of importance.   
 
Due to the physical cavities in the molecular arrangement and thermo-responsive abilities, 
cholestereyl ester systems provide promising possibilities as delivery systems for 
hydrophobic drugs.  The advantages of this liquid crystalline system are the ability to 
incorporate hydrophobic drugs and the possibility to modulate drug release. However, the 
drug loading capacity in this system is relatively smaller than that in systems such as 
polymeric nanoparticles.  This is because the more ordered structures lead to drug 
expulsion, while less perfect structures provide more space to accommodate drugs.  
 
Another drawback of this system is high tendency of drug recrystallization during storage. 
In order to better stabilize this system further investigations would be directed to develop 
this liquid crystalline system into microcapsules, nanoparticles or gels.   
 
Liquid crystalline nanoparticles are usually prepared by high pressure melt 
homogenization or solvent evaporation.  The feature of high pressure melt 
homogenization is to dissolve drug in the melted matrix lipid rather than in organic 
76 
 
solvent.  The first step is to dissolve drug in the melted lipid, heat aqueous phase 
(containing stabilizer) and add into the melted lipid phase to form a crude emulsion.  
Next, transfer the hot emulsion into a heated high-pressure homogenizer.  In the high 
pressure homogenization step, because of high energy input, the emulsion would be 
broken into dispersion of nanoparticles.  Finally, filtrate the dispersion and cool down to 
room temperature.  The different step in solvent evaporation technique is that the matrix 
lipid is dissolved in organic solvent, aqueous phase then mix with the solvent rather than 
with the melted lipid.  In the homogenization step the solvent will be evaporated using a 
rotary evaporator.    
 
This liquid crystalline system would be finally developed into a transdermal drug 
delivery system.  Human skin should be used as the membrane for drug permeation 
studies, and the interaction between the formulation and human skin should be studied. 
Oral administration of the liquid crystalline system is also possible after transforming into 
a conventional dosage form (e.g. tablets or pellets).  
 
We anticipate that future studies will lead to a better understanding of the mechanisms of 
drug release from liquid crystalline matrix and applications of liquid crystals in drug 







Appendix І. Fickian diffusion model 
A1.1 Fick’s First Law of Diffusion 
In transport, the flow (or flux, Ji in mol cm-2 s-1) is related to the velocity of molecular 
movement (υ  in cm s-1) and the concentration (Ci in mol cm-3) of the molecules in 
motion in Equation A1.1 
Ji= Ci υ                                                                                                        (A1.1) 
A fundamental principle of irreversible thermodynamics is that the flow, at any point in 
the system, at any instant, is proportional to the appropriate potential gradient.  It can be 
expressed mathematically for a species i as shown in Equation A1.2 where ii χμ ∂∂ / is the 
gradient and Li is the proportionality constant.  










                                                                                        (A1.2) 
Equation A1.2 is the general form of Fick’s first law of diffusion.  If constant temperature 
and pressure is assumed, Equation A1.2 can be expressed as Equation A1.3 where Di is 







Ci                                                                                        (A1.3) 
 
A1.2 Fick’s Second Law of Diffusion 
 
Fick’s second law relates the rate of change in concentration with time at a given point in 
a system to the rate of change in concentration gradient at that point.  It is expressed in 
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∂                                                           (A1.4) 
Fick’s laws are more applicable if certain parameters or boundaries are specified.  In this 
laboratory, the mathematical boundary conditions imposed are those of a well-designed 
diffusion experiment when the permeant is at a high, fixed activity on one side of an inert 
homogeneous membrane through which it diffuses into a sink on the other side and 
before the start of the experiment the membrane is entirely devoid of permeant.  
 
This implies that the diffusive flow begins at the high-concentration side (the donor side) 
of the membrane where C=C0 and x=h at all time intervals, t.  There is no diffusant 
material within the membrane before ingress of the permeant being modeled, implying 
that at t=0 we have C=0 for all values of x.  Diffusion occurs in the direction of 
decreasing x toward the opposite side of the membrane where x=0 and C=0 (sink 
receptor phase) for all time intervals, t. the cumulative mass Q, of permeant that passes 
through a unit area of a membrane in a time t is shown in equation 1.5 where C0 is the 
concentration of diffusant in the membrane lamina juxtaposed to the donor vehicle, and h 




















DthCQ ππ                                            (A1.5) 
 
As t , the exponential term tends to zero and Fick’s second law has been expanded to 














0                                                                  (A1.6) 
This equation is applicable to typical cumulative mass versus time diffusion plots that 
have an initial non-linear lag time followed by a linear steady state plot.  From Equation 
A1.6, it can solved for t and this yields the lag time (tlag) as described by Equation A1.7 
which relates inversely to the diffusion co-efficient and directly to the diffusional 




=                                                               (A1.7) 
When Equation A1.6 is differential relative to time, Equation A1.8 is obtained, possibly 






dQ 0==                                                                                (A1.8) 
It is often impractical to use the forms of Equations A1.6 and A1.8 as shown because 
they include a term C0 (the concentration of permeant in the outer layer of the membrane), 
that is extremely difficult to measure.  The value C0 is replaced with a term that links it to 
the concentration in the vehicle Cv through the partition co-efficient K, which rearranges 





dQ v==                                                                             (A1.9) 
The product of the partition co-efficient and the donor vehicle concentration will yield 
the diffusant concentration in the membrane lamina.  Therefore, the main variables 
influencing the rate of diffusion are D, K, Cv and h.  Frequently, particularly in biological 
membranes, there is a practical difficulty in measuring the diffusional pathlength and that 
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the information concerning the individual effects of changes in K and D is often not 
required, a composite parameter is usually used to replace these values in Equation A1.9. 
The permeability co-efficient P, is thus defined as P=KD/h, and this simplifies Equation 
A1.9 to further gives Equation A1.10 
vPCJ =                                                                 (A1.10) 
Equation A1.10 is perhaps the most basic and frequently used expression in the routine 
assessment of membrane permeability.  However, the principles upon which this equation 
is based stipulate that the donor concentration is constant and that the diffusion has 





Appendix П.  Abbreviations Used 
 
CCL     Cholesteryl chloride 
C-N     Crystalline-Nematic 
CNN    Cholesteryl nonanoate  
COC    Cholesteryl oleyl carbonate 
DSC     Differential scanning calorimetry 
IBU      Ibuprofen 
LC       Liquid crystal 
MO      Monoolein 
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